SCHEMBL914754

SCHEMBL914754

C=CC(=O)OC(Cc1cccs1)Cc1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.51
RAB9A P51151 6/20 0.42
PSMB5 P28074 1/20 0.41
CTSC P53634 2/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
ALDH1A1 P00352 5/20 0.39
TSHR P16473 2/20 0.39
POLB P06746 3/20 0.38
NPC1 O15118 4/20 0.38
HPGD P15428 3/20 0.38
HTT P42858 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9931139 0.78 CYP2C19 (0.47) CYP2C19RAB9APSMB5CTSCSLC1A3
SCHEMBL28050463 0.76 NPC1 (0.39) CYP2C19RAB9AALDH1A1TSHRPOLB
SCHEMBL28643501 0.76 ALOX5 (0.43) RAB9AALDH1A1TSHRPOLBNPC1
SCHEMBL7270401 0.76 NPC1 (0.49) CYP2C19RAB9ASLC1A3SLC1A2SLC1A1
SCHEMBL16486014 0.73 CYP1A2 (0.46) PKM
SCHEMBL28643500 0.73 THRB (0.51) CYP2C19RAB9ASLC1A3SLC1A2SLC1A1
SCHEMBL27923709 0.72 CYP2C19 (0.51) CYP2C19RAB9ACTSCSLC1A3SLC1A2
SCHEMBL27772992 0.72 CYP2C19 (0.51) CYP2C19RAB9ACTSCSLC1A3SLC1A2
SCHEMBL7270476 0.71 CYP2C19 (0.64) CYP2C19RAB9ACTSCSLC1A3SLC1A2
SCHEMBL9015298 0.71 TSHR (0.58) CYP2C19RAB9AALDH1A1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312290-B2 Curable formulations, cured compositions, and articles derived thereform GENERAL ELECTRIC COMPANY (US) 2007-12-25 US claimed
EP-1799728-A1 CURABLE FORMULATIONS, CURED COMPOSITIONS, AND ARTICLES DERIVED THEREFROM General Electric Company (US) 2007-06-27 EP claimed
WO-2006036489-A1 CURABLE FORMULATIONS, CURED COMPOSITIONS, AND ARTICLES DERIVED THEREFORM GENERAL ELECTRIC COMPANY (US) 2006-04-06 WO claimed
US-20060069222-A1 Curable formulations, cured compositions, and articles derived thereform GENERAL ELECTRIC COMPANY 2006-03-30 US claimed
EP-1984318-B1 HIGH REFRACTIVE INDEX MONOMERS AND (CO)POLYMERS PREPARED THEREFROM OCULENTIS HOLDING BV (NL) 2015-08-26 EP disclosed
US-9103964-B2 Intraocular lenses essentially free from glistenings OCULENTIS HOLDING B.V. (NL) 2015-08-11 US disclosed
US-8216357-B2 Protective coating compositions and devices GENERAL ELECTRIC COMPANY (US) 2012-07-10 US disclosed
US-7923520-B2 High refractive index monomers and (co)polymers prepared therefrom PROCORNEA HOLDING B.V. (NL) 2011-04-12 US disclosed
US-20110073171-A1 PROTECTIVE COATING COMPOSITIONS AND DEVICES GENERAL ELECTRIC COMPANY (US) 2011-03-31 US disclosed
EP-2302006-A1 Protective coating compositions and devices General Electric Company (US) 2011-03-30 EP disclosed
EP-1984761-B1 INTRAOCULAR LENSES ESSENTIALLY FREE FROM GLISTENINGS PROCORNEA HOLDING BV (NL) 2011-03-23 EP disclosed
US-20110021733-A1 INTRAOCULAR LENSES ESSENTIALLY FREE FROM GLISTENINGS PROCORNEA HOLDING B.V. 2011-01-27 US disclosed
US-20090054978-A1 INTRAOCULAR LENSES ESSENTIALLY FREE FROM GLISTENINGS PROCOMEA HOLDING B.V. 2009-02-26 US disclosed
US-20090023879-A1 HIGH REFRACTIVE INDEX MONOMERS AND (CO)POLYMERS PREPARED THEREFROM PROCORNEA HOLDING B.V. 2009-01-22 US disclosed
US-7312290-B2 Curable formulations, cured compositions, and articles derived thereform GENERAL ELECTRIC COMPANY (US) 2007-12-25 US disclosed
US-7271283-B2 High refractive index, UV-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY (US) 2007-09-18 US disclosed
EP-1818690-A1 Intraocular lenses essentially free from glistenings Procornea Holding B.V. (NL) 2007-08-15 EP disclosed
US-20060069222-A1 Curable formulations, cured compositions, and articles derived thereform GENERAL ELECTRIC COMPANY 2006-03-30 US disclosed
EP-1512704-A1 High refractive index, UV-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY (US) 2005-03-09 EP disclosed
US-20050049376-A1 High refractive index, uv-curable monomers and coating compositions prepared therefrom GENERAL ELECTRIC COMPANY 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023879-A1 HIGH REFRACTIVE INDEX MONOMERS AND (CO)POLYMERS PREPARED THEREFROM MACF1, FHIT, ALOX5 CYP2C19 2364/4885RAB9A 2529/4885PSMB5 788/4885
US-20050049376-A1 High refractive index, uv-curable monomers and coating compositions prepared therefrom MACF1, WASF2, THEM6 CYP2C19 2659/4885RAB9A 2801/4885PSMB5 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.